Skip to main content
  • Home
  • Affected by Cancer
  • Healthy living
  • Clinical best practice
  • Research & Data
  • Publications & Resources
  • About Us
  • For Aboriginal and Torres Strait Islander people
  • Publications & Resources
  • Publications & Resources

More at Cancer Australia

Australian Government - Cancer Australia
Home

CANCER AUSTRALIA STATEMENTS

  • Home
  • Breast cancer
  • Metastatic breast cancer

Practice 5

  • Home
  • Home
  • About the Statement
  • How the Statement was developed
  • The 12 Practices
  • Consumer Fact Sheets
  • mobile menu
  • Home
  • Home
  • About the Statement
  • How the Statement was developed
  • The 12 Practices
  • Consumer Fact Sheets
  • Home
  • Breast cancer
  • Metastatic breast cancer
  • Home
  • Home
  • How the Statement was developed
  • The 10 practices
  • Consumer Fact Sheets
  • Print
  • PDF
  • A|A

Practice 5

Appropriate to offer biopsy of accessible metastases to assess biological markers (such as oestrogen and progesterone receptors and HER2 status), and to offer germline genetic testing for BRCA1/2, if the result is likely to lead to a change in the management of patients with metastatic breast cancer.

Consumer Information

Context

Appropriate to offer biopsy of accessible metastases to assess biological markers (such as oestrogen and progesterone receptors and HER2 status), and to offer germline genetic testing for BRCA1/2, if the result is likely to lead to a change in the management of patients with metastatic breast cancer.

Value to patients

Appropriate to offer biopsy of accessible metastases to assess biological markers (such as oestrogen and progesterone receptors and HER2 status), and to offer germline genetic testing for BRCA1/2, if the result is likely to lead to a change in the management of patients with metastatic breast cancer.

Supporting evidence

Appropriate to offer biopsy of accessible metastases to assess biological markers (such as oestrogen and progesterone receptors and HER2 status), and to offer germline genetic testing for BRCA1/2, if the result is likely to lead to a change in the management of patients with metastatic breast cancer.

published: Wed, 25/09/2019 - 20:14
Previous Next
  • Contact Us
  • Copyright
  • Disclaimer
  • Privacy policy
Copyright © 2019 - Cancer Australia